Compare PDEX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDEX | HURA |
|---|---|---|
| Founded | 1978 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.4M | 160.5M |
| IPO Year | 1995 | 2010 |
| Metric | PDEX | HURA |
|---|---|---|
| Price | $62.56 | $2.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $56.00 | $9.50 |
| AVG Volume (30 Days) | 62.1K | ★ 255.5K |
| Earning Date | 05-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 345.00 | 47.93 |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $66,593,000.00 | N/A |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.83 | ★ N/A |
| Revenue Growth | ★ 23.68 | N/A |
| 52 Week Low | $23.52 | $0.41 |
| 52 Week High | $69.86 | $3.43 |
| Indicator | PDEX | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 47.72 |
| Support Level | $60.40 | $1.99 |
| Resistance Level | $68.86 | $2.20 |
| Average True Range (ATR) | 3.11 | 0.18 |
| MACD | -0.43 | -0.01 |
| Stochastic Oscillator | 38.20 | 25.42 |
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.